Trial Profile
A Phase I/II Study of Durvalumab (Medi 4736) and Stereotactic Ablative Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms DurvaRad
- 23 Jun 2023 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.
- 23 Jun 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2024.
- 06 Jun 2023 Results from phase 2, presented at the 59th Annual Meeting of the American Society of Clinical Oncology